

Date: July 10, 2025

BSE Limited

P. J. Towers, Dalal Street, Fort,
Complex, Mumbai- 400 001
BSE scrip code: 543635

National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla
Bandra (East), Mumbai - 400 051
NSE Symbol: PPLPHARMA

**Sub: Disclosure under Regulation 30 of Securities and Exchange Board of India
(Listing Obligations and Disclosure Requirements) Regulations, 2015
(‘SEBI Listing Regulations’) – ESG Rating**

Dear Sir / Madam,

With reference to the captioned subject, please note that as per the information received by the Company on July 08, 2025, NSE Sustainability Ratings and Analytics Limited (‘NSE Sustainability’), has assigned an Environment, Social, and Governance (‘ESG’) Rating of ‘61’ for the Company for the FY 2023-24 based on data made available by the Company in public domain for that year.

The link for the rating as published is also available on the website of NSE Sustainability - [NSE Sustainability Ratings & Analytics](#).

Please note that the Company has not engaged NSE Sustainability for ESG Rating. NSE Sustainability has voluntarily prepared the report considering the ESG factors reported by the Company.

This intimation is also being uploaded on the website of the Company at <https://www.piramalpharma.com/>.

Kindly treat this intimation for your information and record.

Yours truly,

For Piramal Pharma Limited

Tanya Sanish
Company Secretary

Piramal Pharma Limited

CIN: L24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India

T: +91 22 3802 3000 / 4000; Email: shareholders.ppl@piramal.com

piramalpharma.com